Action Potential Venture Capital

Action Potential Venture Capital intends to build a portfolio of five to seven companies over the next five years. The fund will focus investments in three areas: - New start-up companies that aim to pursue the vision of bioelectronic medicines - Existing companies with technologies that are interacting with the peripheral nervous system through first-generation devices that can stimulate or block electrical impulses - Companies advancing technology platforms that will underpin these treatment modalities Action Potential Venture Capital will be based in Cambridge, Massachusetts and managed by a small, dedicated team. The fund has named Imran Eba as its first partner. Imran will move from GSK’s Worldwide Business Development organisation and work closely with the Bioelectronics R&D unit.